In a bid to relieve students and the business travelers, the Serum Institute of India has requested the Centre to take up the matter of inclusion of Covishield vaccine in the EU COVID19 vaccination passport with the European Union and other countries. The issue will also cause severe disruptions to the Indian and global economy.
At present, only four vaccines have been approved by the European Medicines Agency and those were the jabs from Pfizer/BioNTech, Moderna, Vaxzervria by AstraZeneca/Oxford and Johnson & Johnson's Jenssen. People who have taken vaccines of these companies will be allowed to travel within the EU during the pandemic.
On 28 June Poonawalla said that he has taken up the issue faced by the Indians who have taken the Covishield jab while travelling to the European Union at the highest levels.In a letter of communication with the External Affairs Minister S Jaishankar, the CEO of SII, Adar C Poonawalla said, ''India has a large population. However, not including Covishield in the EU COVID-19 Vaccination Passport will not allow Covishield vaccinated people to travel to European countries and this will affect students, business travellers back and forth, and cause severe disruptions to our economy and to the global economy".
This will in turn affect the economy of India as well as the world. In his letter, Poonawalla has already mentioned that 30 crore people have been vaccinated with Covishield in India so far and it is expected that finally more than 50 per cent of the Indian population will be protected with Covishield vaccination.
The letter also mentions that AstraZeneca-SII Covishield has been manufactured under technology transfer from Oxford/AstraZeneca. Clinical trial of the vaccine have been conducted successfully abroad and has been approved by MHRA for emergency use only. On 28 June Poonawalla said that he has taken up the issue faced by the Indians who have taken the Covishield jab while travelling to the European Union at the highest levels.